Yoko Kataoka1,2, Tomoyuki Igarashi3, Yasuhiko Ohshio3, Takuya Fujita4, Jun Hanaoka3. 1. Department of Surgery, Shiga University of Medical Science, Seta- Tsukinowa, Otsu, Shiga, 520-2192, Japan. ykataoka@belle.shiga-med.ac.jp. 2. Department of General Thoracic Surgery, Kohka Public Hospital, Matsuo, Minakuchi, Koka, Shiga, 528-0074, Japan. ykataoka@belle.shiga-med.ac.jp. 3. Department of Surgery, Shiga University of Medical Science, Seta- Tsukinowa, Otsu, Shiga, 520-2192, Japan. 4. Department of General Thoracic Surgery, Kohka Public Hospital, Matsuo, Minakuchi, Koka, Shiga, 528-0074, Japan.
Abstract
OBJECTIVE: The predictive importance of galectin-3 in non-small cell lung cancer (NSCLC) has not been elucidated. We examined whether galectin-3 could serve as a predictor for tumor recurrence in NSCLC. METHODS: In 42 consecutive patients with NSCLC who underwent radical resection, galectin-3 expression in tumor cells was examined by immunohistochemistry. Galectin-3 levels in serum were assessed before surgery and 1 month after surgery by enzyme-linked immunosorbent assays. RESULTS: Higher expression of galectin-3 in tumor cells was associated significantly with lymphatic invasion (p = 0.049) and tumor recurrence (p = 0.001). The Kaplan-Meier curves for relapse-free survival after radical resection showed that patients with high expression of galectin-3 had significantly shorter relapse-free survival than those with low expression of galectin-3 (p < 0.001). The serum level of galectin-3 was not reduced after radical resection, and there was no significant correlation between the serum level of galectin-3 and recurrence. CONCLUSIONS: Galectin-3 expression in tumor cells could serve as a predictive factor for recurrence, but serum level of galectin-3 is not useful for predicting NSCLC recurrence.
OBJECTIVE: The predictive importance of galectin-3 in non-small cell lung cancer (NSCLC) has not been elucidated. We examined whether galectin-3 could serve as a predictor for tumor recurrence in NSCLC. METHODS: In 42 consecutive patients with NSCLC who underwent radical resection, galectin-3 expression in tumor cells was examined by immunohistochemistry. Galectin-3 levels in serum were assessed before surgery and 1 month after surgery by enzyme-linked immunosorbent assays. RESULTS: Higher expression of galectin-3 in tumor cells was associated significantly with lymphatic invasion (p = 0.049) and tumor recurrence (p = 0.001). The Kaplan-Meier curves for relapse-free survival after radical resection showed that patients with high expression of galectin-3 had significantly shorter relapse-free survival than those with low expression of galectin-3 (p < 0.001). The serum level of galectin-3 was not reduced after radical resection, and there was no significant correlation between the serum level of galectin-3 and recurrence. CONCLUSIONS:Galectin-3 expression in tumor cells could serve as a predictive factor for recurrence, but serum level of galectin-3 is not useful for predicting NSCLC recurrence.
Authors: Y Honjo; H Inohara; S Akahani; T Yoshii; Y Takenaka; J Yoshida; K Hattori; Y Tomiyama; A Raz; T Kubo Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: Feng-Ming Kong; Randall K Ten Haken; Matthew J Schipper; Molly A Sullivan; Ming Chen; Carlos Lopez; Gregory P Kalemkerian; James A Hayman Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Fabio Puglisi; Alessandro Marco Minisini; Fabio Barbone; Donatella Intersimone; Giuseppe Aprile; Cinzia Puppin; Giuseppe Damante; Igor Paron; Gianluca Tell; Andrea Piga; Carla Di Loreto Journal: Cancer Lett Date: 2004-08-30 Impact factor: 8.679
Authors: Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Jürgen Serth; Stephan Kruck; Alfredo Gracia; Arnulf Stenzl; Markus A Kuczyk Journal: World J Urol Date: 2008-07-02 Impact factor: 4.226